Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

The aim is to find new uses of real-world data in AI development, and to help health systems move from fragmented, compliance ...

Red and blue teams often operate independently, but attackers don't. Picus Security shows how continuous purple teaming and ...

Q3 2025 Management View CEO Steven Lo announced a major partnership with Dynavax, under which Vaxart could receive up to $700 million in license, regulatory, and milestone fees, as well as royalties ...

Astrology offers insights into personal well-being for November 13, 2025. Each zodiac sign receives tailored advice, ...

On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay’s head-to ...

Senate Majority Leader John Thune says it's up to Democrats whether they accept a deal in front of them to end the government ...

Here are ten red flags that reveal a man who looks ambitious — but is quietly going nowhere in life. Talk is easy. Action is ...

PolyPid Ltd. (NASDAQ: PYPD) Q3 2025 Earnings Call Transcript November 12, 2025 PolyPid Ltd. beats earnings expectations.

Q3 2025 Earnings Call November 13, 2025 5:00 PM ESTCompany ParticipantsKelly Goodman - Interim CEO & Corporate ...

Learn how the European Union’s Corporate Sustainability Reporting Directive (CSRD) is designed to enhance the transparency of ...

Site onboarding varies by location due to individual site constraints and policies.